Targeting myocardial substrate metabolism in heart failure: potential for new therapies

Hossein Ardehali; Hani N Sabbah; Michael A Burke; Satyam Sarma; Peter P Liu; John G.F Cleland; Aldo Maggioni; Gregg C Fonarow; E. Dale Abel; Umberto Campia; Mihai Gheorghiade

doi:10.1093/eurjhf/hfr173

Back

Targeting myocardial substrate metabolism in heart failure: potential for new therapies

Journal article

Open access

Peer reviewed

Targeting myocardial substrate metabolism in heart failure: potential for new therapies

Hossein Ardehali, Hani N Sabbah, Michael A Burke, Satyam Sarma, Peter P Liu, John G.F Cleland, Aldo Maggioni, Gregg C Fonarow, E. Dale Abel, Umberto Campia, …

European journal of heart failure, Vol.14(2), pp.120-129

02/2012

DOI: 10.1093/eurjhf/hfr173

PMCID: PMC3260022

PMID: 22253453

Files and links (1)

url

https://doi.org/10.1093/eurjhf/hfr173View

Published (Version of record) Open Access

Abstract

The incidence and prevalence of heart failure have increased significantly over the past few decades. Available data suggest that patients with heart failure independent of the aetiology have viable but dysfunctional myocardium that is potentially salvageable. Although a great deal of research effort has focused on characterizing the molecular basis of heart failure, cardiac metabolism in this disorder remains an understudied discipline. It is known that many aspects of cardiomyocyte energetics are altered in heart failure. These include a shift from fatty acid to glucose as a preferred substrate and a decline in the levels of ATP. Despite these demonstrated changes, there are currently no approved drugs that target metabolic enzymes or proteins in heart failure. This is partly due to our limited knowledge of the mechanisms and pathways that regulate cardiac metabolism. Better characterization of these pathways may potentially lead to new therapies for heart failure. Targeting myocardial energetics in the viable and potentially salvageable tissue may be particularly effective in the treatment of heart failure. Here, we will review metabolic changes that occur in fatty acid and glucose metabolism and AMP-activated kinase in heart failure. We propose that cardiac energetics should be considered as a potential target for therapy in heart failure and more research should be done in this area.

Energetics

Heart failure

Cardiac metabolism

Reviews

AMP-activated kinase

Details

Title: Subtitle: Targeting myocardial substrate metabolism in heart failure: potential for new therapies
Creators: Hossein Ardehali - , USA
Hani N Sabbah - , USA
Michael A Burke - , USA
Satyam Sarma - , USA
Peter P Liu
John G.F Cleland
Aldo Maggioni
Gregg C Fonarow
E. Dale Abel
Umberto Campia - , USA
Mihai Gheorghiade - , USA
Resource Type: Journal article
Publication Details: European journal of heart failure, Vol.14(2), pp.120-129
DOI: 10.1093/eurjhf/hfr173
PMID: 22253453
PMCID: PMC3260022
NLM abbreviation: Eur J Heart Fail
ISSN: 1388-9842
eISSN: 1879-0844
Publisher: Oxford University Press
Language: English
Date published: 02/2012
Academic Unit: Roy J. Carver Department of Biomedical Engineering; Fraternal Order of Eagles Diabetes Research Center; Biochemistry and Molecular Biology; Endocrinology and Metabolism; Internal Medicine
Record Identifier: 9984025253902771

Metrics

18 Record Views

129 Times Cited - Web of Science